A possible interaction of potential clinical interest between digoxin and acarbose

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 5, 1996, Pages 589-592

  Serrano, José S ^a,b   Jiménez, Carmen M ^a   Serrano, María I ^a   Balboa, Begoña ^a  

^a Facultad de Medicina ^*

^b Facultad de Medicina   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; DIGOXIN;

AGED; ARTICLE; CASE REPORT; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; HEART FAILURE; HUMAN; PRIORITY JOURNAL;

EID: 0029848320     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90156-3     Document Type: Article

References (23)

1. Buchanan DR. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin-dependent diabetes. Eur J Clin Pharmacol 1988;34:51-3.
2. Viviani GL. Acarbose treatment in insulin-dependent diabetics. Curr Ther Res 1987;42:1-11.
3. Toeller M. Alpha-glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Invest 1994;24 (suppl 3):31-5.
4. Toeller M. Inhibitors of alpha glucosidase. J Annu Diabetol 1991;36:203-12.
5. Dimitriadis G, Raptis S. Alpha-glucosidase inhibition in the treatment of diabetes mellitus. Horm Metab Res 1992;26 (suppl):42-9.
6. Rios MS. Acarbose and insulin therapy in type I diabetes mellitus. Eur J Clin Invest 1994;24 (suppl 3):36-9.
7. Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest 1994;24 (suppl 3):3-10.
8. Hollander P. Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992;44 (suppl 3):49-53.
9. Kozma C, Rabasseda X. Acarbose: inhibitor of α-glucosidase. Drugs Today 1994;30 (suppl 1):1-43.
10. Pullar T. Compliance with drug therapy. Br J Clin Pharmacol 1991;32:535-9.
11. Durán JA, Figuerola J. Cumplimiento de la medicación: características, factores que lo determinan y recomendaciones para mejorarlo. Med Clin 1988;90: 338-43.
12. Hansten PD. Drug interactions. 5th ed. Philadelphia: Lea & Febiger, 1985.
13. Castillo JR, Carrasco A, De la Torre F. Effects of benzodiazepines on digoxin tissue concentrations and plasma protein binding. J Pharm Pharmacol 1983;35: 462-3.
14. Serrano JS, De la Torre F, Castillo JR, Hevia A. Efecto del diacepán sobre el comportamiento farmacocinético de la betametil-digoxina [abstract]. J Pharmacol 1983;14:566.
15. Castillo JR, De la Torre F, Serrano JS. Modification de l'union de la bêta-méthyl-digoxine aux proteines plasmatiques par diverses benzodiazépines in vitro [abstract]. Thérapie 1984;39:80.
16. Castillo JR, Pérez-Ojeda E, Encina JL, Serrano JS. Modification of the inotropic effect of digoxin by diazepam in rat left atria. J Pharm Pharmacol 1985;37: 828-9.
17. Friedel HA, Todd PA. Nabumetone: a reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 1993;45:131-56.
18. Khalel SAH. The uptake of digoxin and digitoxin by some antacids. J Pharm Pharmacol 1974;26:961-7.
19. McElnay JC, Harron DWG, D'Arcy PF, Eagle MRG. Interaction of digoxin with antacid constituents [letter]. Br Med J 1978;1:1554.
20. Ascione FJ, Poirier TI. Digitalis with antiacids [letter]. Drug Ther 1979;9:157.
21. Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988;35: 214-43.
22. Pagano G. Comparison of acarbose and phenphormin treatment in glibenclamide-treated non-insulin dependent diabetics. Curr Ther Res 1986; 39:143-8.
23. Hillebrand I. Efficacy and tolerability of a 12 week treatment with acarbose, miglitol, and glibenclamide [abstract]. Diabetes 1987;26:134A.